200 results on '"Muñoz-Calleja, Cecilia"'
Search Results
2. NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
3. Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy
4. Dasatinib-induced spleen contraction leads to transient lymphocytosis
5. Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation
6. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody
7. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
8. Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation
9. PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study.
10. Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis.
11. Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis
12. Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease
13. A Neutrophil Timer Coordinates Immune Defense and Vascular Protection
14. Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis
15. Evaluation of the novel therapeutic anti‐CCR7 antibody CAP‐100 as an add‐on therapy in chronic lymphocytic leukemia patients receiving venetoclax
16. CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
17. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease
18. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
19. Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors
20. Gluathione is critical for the growth of lymphoma-initiating cells and lymphomagenesis in vivo
21. Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study
22. Perez-Chacon et al=SUPPLEMENTARY INFORMATION from Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
23. Data from Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
24. Dasatinib-induced spleen contraction leads to transient lymphocytosis
25. Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy
26. Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors
27. CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects
28. Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
29. Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients
30. Kv1.3 channel inhibition by indolic compounds
31. CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects
32. A Differential Signature of Circulating miRNAs and Cytokines Between COVID-19 and Community-Acquired Pneumonia Uncovers Novel Physiopathological Mechanisms of COVID-19
33. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia
34. Circulating miRNAs and Cytokines Uncover Novel Physiopathological Mechanisms of COVID-19
35. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
36. Esclerosis sistémica y enfermedad mixta del tejido conectivo
37. Coordinadores y autores
38. Monitoring and safety of CAR-T therapy in clinical practice
39. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody
40. Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors.
41. Additional file 1 of CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
42. Additional file 1 of CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
43. Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID‐19 patients
44. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
45. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
46. Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID‐19 patients
47. Detection of SARS-Cov-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients
48. Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL
49. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
50. COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.